摘要
目的:探讨替格瑞洛对冠状动脉多支病变(MVD)患者行不完全血运重建(ICR)后的预后影响。方法:多支病变并接受经皮冠状动脉介入术(PCI)ICR患者115例随机分为替格瑞洛组(A组)50例和氯吡格雷组(B组)65例。记录2组患者的基线资料、冠状动脉病变特征、介入手术情况以及出血并发症等不良反应,并电话或门诊随访1年,比较两组不良心血管事件发生率及再次血运重建情况。结果:A组和B组基线临床资料、冠状动脉病变特征、介入手术情况、出血不良反应均无统计学差异(P>0.05)。随访1年时间,A组、B组不良心血管事件发生率无统计学意义(P>0.05)。A组再次血运重建率明显低于B组(P<0.05)。结论:替格瑞洛能够使ICR的MVD患者再次血运重建率降低,可改善该类患者的预后。
[ABSTRACT]Objective:To investigate the effects of ticagrelor on the prognosis of coronary multivessel lesions (MVD) patients undergoing incomplete revasculariztion(ICR). Methods: Multivessel disease and accepted percutaneous coronary intervention operation(PCI) in patients with ICR 115 cases were randomly divided into ticagrelor group (A group) 50 cases and clopidogrel group (B group) 65 cases. Baseline data of 2 groups were recorded, including characteristics of coronary artery disease, Interventional procedures, bleeding complications, adverse reactions, and results of 1 year of telephone or outpatient follow-up were also recorded. The latter included adverse cardiovascular events and repeated revascularization. Results:The differences of baseline clinical data of A group and B group, including characteristics of coronary artery disease, interventional operation, bleeding adverse reactions are not statistically signiifcant(P>0.05). After 1 year of follow-up, regarding of the occurrence rate of adverse cardiovascular events of A group and B group, there is no statistically signiifcant difference(P>0.05). However, revascularization rate of A group is signiifcantly lower than B group(P<0.05). Conclusion: In comparison with clopidogrel, ticagrelor may lower the revascularization rate of MVD patients accepted ICR, which in turn can improve the prognosis of the kind of patients.
出处
《中国医药导刊》
2016年第3期288-289,291,共3页
Chinese Journal of Medicinal Guide
关键词
冠状动脉多支病变
替格瑞洛
不完全血运重建
预后
Multivessel coronary artery disease
Ticagrelor
Incomplete revascularization
Prognosis
